A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care
NCT ID: NCT06693531
Last Updated: 2026-01-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
350 participants
OBSERVATIONAL
2024-11-22
2030-05-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this research study is to look at how DUPIXENT is used in normal care of patients with EoE.
Possible benefits to others include a better understanding of EoE and helping to inform research and clinical trial design leading to treatment decisions in this patient population going forward.
Patient questionnaires will measure the following:
* How EoE makes one feel
* EoE signs and/or symptoms, eg, how difficult it is to swallow
* How EoE affects quality-of-life
* How EoE impacts aspects of daily life
* How EoE symptoms have changed throughout the study
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Dupilumab in Adult Participants With Active Eosinophilic Esophagitis (EoE)
NCT02379052
Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)
NCT03633617
A Non-interventional Observational Study to Assess Long-term Efficacy and Safety of Dupilumab for the Treatment of Patients (>= 12 Years) With Eosinophilic Esophagitis Under Real-world-conditions in Germany
NCT06695897
A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis
NCT07112378
A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)
NCT06101095
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
EoE Patients treated with DUPIXENT®
dupilumab
No investigational agents will be provided. Dupilumab will be prescribed as per usual clinical practice and will not be provided by the sponsor.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
dupilumab
No investigational agents will be provided. Dupilumab will be prescribed as per usual clinical practice and will not be provided by the sponsor.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Participants aged ≥12 years and caregivers or legal guardians of participants aged \<12 years must be able to understand and complete registry-related questionnaires
Exclusion Criteria
2. Treatment with DUPIXENT® within the 6 months prior to the screening assessment
3. Participation in an ongoing interventional study on or within 6 months of the baseline assessment. Once enrolled in registry, participation is allowed in other ongoing studies (at the discretion of the registry investigator)
1 Year
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sanofi
INDUSTRY
Regeneron Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trial Management
Role: STUDY_DIRECTOR
Regeneron Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Phoenix Childrens Hospital
Phoenix, Arizona, United States
Arizona Digestive Health/GI Alliance
Sun City, Arizona, United States
Arkansas Childrens Hospital
Little Rock, Arkansas, United States
Scripps Clinic
La Jolla, California, United States
University of California Los Angeles (UCLA)
Los Angeles, California, United States
University of Southern California Keck School of Medicine
Los Angeles, California, United States
University of California, San Francisco
Oakland, California, United States
University of California San Francisco (UCSF)
San Francisco, California, United States
Childrens Hospital Colorado
Aurora, Colorado, United States
University of Colorado Anschutz Medical Campus
Aurora, Colorado, United States
Rocky Mountain Gastroenterology
Littleton, Colorado, United States
UConn Health - The Carole and Ray Neag Comprehensive Cancer Center
Farmington, Connecticut, United States
Yale School of Medicine
New Haven, Connecticut, United States
Gastroenterology of Greater Orlando
Orange City, Florida, United States
Orlando Health
Orlando, Florida, United States
Emory Healthcare, Emory Clinic
Atlanta, Georgia, United States
GI Care for Kids LLC
Atlanta, Georgia, United States
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, United States
Northwestern University, Feinberg School of Medicine
Chicago, Illinois, United States
Comprehensive Gastrointestinal Health, LLC
Libertyville, Illinois, United States
NorthShore University Health System
Skokie, Illinois, United States
Kansas Gastroenterology LLC
Wichita, Kansas, United States
Allergy & Asthma Specialists, P.S.C.
Owensboro, Kentucky, United States
Boston Specialists
Boston, Massachusetts, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Boston Childrens Hospital
Boston, Massachusetts, United States
Mayo Clinic
Rochester, Minnesota, United States
GI Associates and Endoscopy Center
Flowood, Mississippi, United States
Kansas City VA Medical Center
Kansas City, Missouri, United States
Washington University in Saint Louis
St Louis, Missouri, United States
Allergy Partners of N.J., P.C.
Ocean City, New Jersey, United States
Steven And Alexandra Cohen Children's Medical Center Of New York
Lake Success, New York, United States
Weil Cornell Medicine NYP
New York, New York, United States
Icahn School of Medicine at Mount Sinai
New York, New York, United States
Gastroenterology Group of Rochester LLP
Rochester, New York, United States
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
Duke University
Durham, North Carolina, United States
Atrium Health / Wake Forest University School of Medicine
Winston-Salem, North Carolina, United States
Great Lakes Gastroenterology Research, LLC
Mentor, Ohio, United States
Susquehanna Research Group
Camp Hill, Pennsylvania, United States
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Medical University of South Carolina
Charleston, South Carolina, United States
Palmetto Gastroenterology Clinical Research
Summerville, South Carolina, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Brooke Army Medical Center
Fort Sam Houston, Texas, United States
Baylor College of Medicine
Houston, Texas, United States
GI Alliance
Southlake, Texas, United States
Tanner Clinic
Layton, Utah, United States
University of Utah
Salt Lake City, Utah, United States
University of Virginia
Charlottesville, Virginia, United States
Seattle Children's Home Health Company
Seattle, Washington, United States
Washington Gastroenterology, GIA
Tacoma, Washington, United States
Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
R668-EE-2328
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.